H.B. Fuller Company Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw strong revenue, EBITDA, and EPS growth, with margin expansion and robust cash flow. The announced AMS acquisition is expected to accelerate growth, expand the medical segment, and deliver significant synergies, while a disciplined deleveraging plan is in place.
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals passing. No shareholder questions were submitted during the Q&A session.
-
Q1 2026 saw margin expansion and profit growth despite a 6.6% organic revenue decline, as swift pricing actions and supply chain agility offset raw material shortages from Middle East disruptions. Guidance for 2026 was raised, with strong EBITDA and EPS outlooks.
Fiscal Year 2025
-
Q4 saw strong margin expansion and double-digit EPS growth despite revenue declines, with EBITDA at the top end of guidance. 2026 outlook calls for flat to modest revenue growth, continued margin gains, and robust M&A activity, even as macro headwinds persist.
-
The company is targeting over 20% EBITDA margins by 2028, driven by Project Quantum Leap, disciplined M&A, and a shift toward higher-value segments. Financial guidance includes 5%+ revenue growth and strong cash generation, with a focus on innovation, operational excellence, and portfolio optimization.
-
Q3 saw margin expansion and double-digit EPS growth despite economic headwinds, with strong execution in pricing, cost control, and portfolio optimization. Guidance for 2025 was tightened, with EBITDA and EPS growth expected, though cash flow is temporarily reduced due to higher inventory for footprint optimization.
-
Q2 2025 saw strong margin expansion and profit growth, driven by portfolio shifts, cost savings, and pricing actions, despite subdued global demand and volume softness. Full-year guidance was raised for EBITDA and EPS, with continued focus on innovation, sustainability, and operational excellence.
-
The meeting covered director elections, auditor ratification, executive compensation, and incentive plan amendments, with all proposals approved. No shareholder questions were received during the Q&A session.
-
Q1 saw 1.9% organic revenue growth and strong share gains in HHC and China, but higher raw material costs compressed margins. Guidance for 2025 is unchanged, with EBITDA expected to grow 1%-5% and a focus on share buybacks over M&A due to elevated leverage.
Fiscal Year 2024
-
Fiscal 2024 ended with weaker-than-expected Q4 results due to broad volume deceleration and raw material cost pressures, but full-year margins reached record levels. Strategic actions include major footprint reduction, targeted acquisitions, and a focus on higher-margin segments, with 2025 guidance reflecting a challenging but manageable environment.
-
EBITDA margin and organic growth improved year-over-year, with strong performance in construction adhesives and most HHC segments, but EA was impacted by solar market weakness. Guidance was narrowed due to lower volume expectations, while acquisitions and restructuring continue to support margin expansion.
-
Q2 saw strong volume growth across all segments, 10% adjusted EBITDA growth, and margin expansion. Guidance for 2024 was raised, reflecting robust performance and the ND Industries acquisition, with continued focus on restructuring, innovation, and capital allocation.